Pfizer (NYSE:PFE) Price Target Cut to $44.00 by Analysts at Wells Fargo & Company

Pfizer (NYSE:PFE – Get Rating) had its price target lowered by Wells Fargo & Company from $50.00 to $44.00 in a report issued on Friday morning, The Fly reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the company. Bank of America cut Pfizer from a buy rating to a neutral rating and set a $60.00 target price for the company. in a research note on Wednesday, January 4th. StockNews.com started coverage on Pfizer in a research note on Thursday. They set a buy rating for the company. JPMorgan Chase & Co. set a $45.00 price objective on Pfizer in a research note on Monday, February 27th. UBS Group set a $45.00 price objective on Pfizer in a research note on Tuesday. Finally, Credit Suisse Group reduced their price objective on Pfizer from $54.00 to $50.00 and set an outperform rating for the company in a research note on Wednesday, February 1st. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $50.38.

Pfizer Trading Down 0.7 %

Shares of PFE stock traded down $0.27 on Friday, hitting $40.10. The company had a trading volume of 57,457,785 shares, compared to its average volume of 24,156,295. The firm has a market cap of $225.33 billion, a P/E ratio of 7.32, a P/E/G ratio of 1.33 and a beta of 0.64. The stock’s 50-day moving average is $43.26 and its two-hundred day moving average is $46.03. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22. Pfizer has a twelve month low of $39.23 and a twelve month high of $56.32.

Pfizer (NYSE:PFE – Get Rating) last released its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, topping the consensus estimate of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The business had revenue of $24.30 billion during the quarter, compared to analysts’ expectations of $24.40 billion. During the same quarter last year, the firm posted $1.08 earnings per share. The firm’s revenue was up 1.9% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer will post 3.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Lam Group Inc. bought a new stake in Pfizer during the fourth quarter worth $25,000. Worth Asset Management LLC bought a new stake in shares of Pfizer in the first quarter valued at $29,000. Karp Capital Management Corp bought a new stake in shares of Pfizer in the third quarter valued at $27,000. My Personal CFO LLC bought a new stake in shares of Pfizer in the fourth quarter valued at $32,000. Finally, Mendota Financial Group LLC bought a new stake in shares of Pfizer in the fourth quarter valued at $33,000. Institutional investors own 67.62% of the company’s stock.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.